SEC Form 10-K filed by Supernus Pharmaceuticals Inc.
$SUPN
Biotechnology: Pharmaceutical Preparations
Health Care
Unavailable
Unavailable
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/19/2025 | $57.00 → $36.00 | Overweight → Neutral | Cantor Fitzgerald |
| 1/6/2025 | $57.00 | Overweight | Cantor Fitzgerald |
| 9/11/2024 | $41.00 → $36.00 | Overweight → Neutral | Piper Sandler |
| 1/3/2023 | $44.00 → $45.00 | Buy | Jefferies |
| 12/1/2021 | $40.00 → $44.00 | Buy | Jefferies |
4 - SUPERNUS PHARMACEUTICALS, INC. (0001356576) (Issuer)
4 - SUPERNUS PHARMACEUTICALS, INC. (0001356576) (Issuer)
4 - SUPERNUS PHARMACEUTICALS, INC. (0001356576) (Issuer)
Cantor Fitzgerald downgraded Supernus Pharma from Overweight to Neutral and set a new price target of $36.00 from $57.00 previously
Cantor Fitzgerald initiated coverage of Supernus Pharma with a rating of Overweight and set a new price target of $57.00
Piper Sandler downgraded Supernus Pharma from Overweight to Neutral and set a new price target of $36.00 from $41.00 previously
8-K - SUPERNUS PHARMACEUTICALS, INC. (0001356576) (Filer)
8-K - SUPERNUS PHARMACEUTICALS, INC. (0001356576) (Filer)
8-K - SUPERNUS PHARMACEUTICALS, INC. (0001356576) (Filer)
Proposed acquisition expected to accelerate mid- to long-term revenue and cash flow growth and further diversify revenue base.Strengthens Supernus' leading presence in neuropsychiatric conditions with an innovative commercial product, ZURZUVAE® (zuranolone), and a novel CNS discovery platform.Expected to be significantly accretive in 2026 with potential cost synergies of up to $200 million on an annual basis.Upfront cash payment of $8.50 per share, plus one non-tradable contingent value right (CVR) payable upon achieving certain specific milestones collectively worth up to $3.50 per share in cash, for an aggregate of up to approximately $795 million or $12.00 per share.Supernus to host confe
ROCKVILLE, Md., May 29, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals is expanding its partnership with TV personality and sports reporter Jay Glazer in a new content series featuring his wife, Rosie Glazer. The series, which launches its first episode on the All About ADHD YouTube channel in May for Mental Health Awareness Month, offers an intimate look at how ADHD impacts relationships and how Qelbree (viloxazine extended-release capsules), a non-stimulant ADHD treatment for people 6 years and older, has played a role in Jay's ADHD treatment journey. The four-part video series delves into Jay's experience with ADHD through the lens of his relationship with Rosie, offering unique pe
ROCKVILLE, Md., May 28, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company received Paragraph IV Notice Letters from third parties notifying Supernus that the third parties submitted Abbreviated New Drug Applications (ANDAs) for viloxazine extended-release capsules, eq. 100, 150, and 200 mg base. Supernus is currently reviewing the details of these Notice Letters and intends to vigorously enforce its intellectual property rights relating to Qelbree. The U.S. Food and Drug Administration's Orange Book
SC 13G/A - SUPERNUS PHARMACEUTICALS, INC. (0001356576) (Subject)
SC 13G/A - SUPERNUS PHARMACEUTICALS, INC. (0001356576) (Subject)
SC 13G - SUPERNUS PHARMACEUTICALS, INC. (0001356576) (Subject)
Proposed acquisition expected to accelerate mid- to long-term revenue and cash flow growth and further diversify revenue base.Strengthens Supernus' leading presence in neuropsychiatric conditions with an innovative commercial product, ZURZUVAE® (zuranolone), and a novel CNS discovery platform.Expected to be significantly accretive in 2026 with potential cost synergies of up to $200 million on an annual basis.Upfront cash payment of $8.50 per share, plus one non-tradable contingent value right (CVR) payable upon achieving certain specific milestones collectively worth up to $3.50 per share in cash, for an aggregate of up to approximately $795 million or $12.00 per share.Supernus to host confe
First quarter 2025 net sales of Qelbree® increased 44% to $64.7 million, compared to the same period in 2024.First quarter 2025 net sales of GOCOVRI® increased 16% to $30.7 million, compared to the same period in 2024.First quarter 2025 total revenues increased 4% to $149.8 million, compared to the same period in 2024. First quarter 2025 total revenues excluding Trokendi XR® and Oxtellar XR® net sales (non-GAAP)(1) increased 26% compared to the first quarter of 2024.First quarter 2025 operating loss of $(10.3) million, compared to operating loss of $(3.2) million in 2024. First quarter adjusted operating earnings (non-GAAP)(1) increased 16% to $25.9 million.ONAPGO™ (apomorphine hydrochloride
ROCKVILLE, Md., April 23, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report financial and business results for the first quarter of 2025 after the market closes on Tuesday, May 6, 2025. Jack Khattar, President and CEO, and Tim Dec, Senior Vice President and CFO, will host a conference call to present the first quarter 2025 financial and business results on Tuesday, May 6, 2025 at 4:30 p.m. ET. Following management's prepared remarks and discussion of business results, the call will
Jay is sharing his story of receiving an ADHD diagnosis and eventually finding his treatment approach with Qelbree15.7 million U.S. children, teens and adults estimated to have been diagnosed with ADHD1,2 ROCKVILLE, Md., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Television personality and sports reporter Jay Glazer is opening up about his personal experiences with attention-deficit/hyperactivity disorder (ADHD) – one of the most common psychiatric diagnoses affecting approximately 10 million adults in the U.S. – and with Qelbree (viloxazine extended-release capsules), a nonstimulant medication for the treatment of ADHD.3 Glazer, who has always been outspoken about his mental health struggles, wa